Novo Nordisk To Appeal Decision On Norditropin
Danish drug maker Novo Nordisk has decided to appeal a court decision that rendered its patent for recombinant human growth hormone invalid and unenforceable due to inequitable conduct....To view the full article, register now.
Already a subscriber? Click here to view full article